Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Shi, Yujiao; Dong, Guoju; Liu, Jiangang; Shuang, Xiong; Liu, Chunqiu; Yang, Chenguang; Wang, Qing; Qiao, Wenbo

doi:10.3389/fcvm.2022.854501

Cited by 15 publications

(9 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, plasma galectin-3 levels were markedly increased in HF than in the controls. Similar results were reported by Shi Y et al [12] and Jiang J et al [13]. Further, in this study, the levels of galectin-3 increased significantly as age increased.…”

Section: Discussionsupporting

confidence: 92%

Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study

Bi¹,

Santhosh²,

Sigamani³

2022

Cureus

View full text Add to dashboard Cite

Heart failure (HF) is a progressive clinical syndrome resulting from various cardiac disorders. Galectin-3 promotes adverse cardiac remodeling leading to chronic heart failure (CHF). AimTo estimate the levels of galectin-3 in chronic heart failure (CHF) patients and controls and to determine the association between galectin-3 levels with age, gender, and left ventricular ejection fraction (LVEF). Materials and methodsThe levels of plasma galectin-3 were estimated in CHF patients from January 2013 to October 2013 at Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu. The study was a case-control study. A total of 55 CHF patients were recruited as cases, and 55 controls were enrolled for the study. Participants' profiles were documented, and 5 mL of blood sample was collected. Galectin-3 levels in plasma were estimated by using an enzyme-linked immunosorbent assay (ELISA). Data were analyzed using SPSS 25.0 version. Mean, SD, and percentages were used to compare the characteristics of the two groups. The student's ttest was used to compare galectin-3 levels between CHF patients and the controls. ANOVA was employed to compare galectin-3 levels in the different age groups, gender, and LVEF. The receiver operating characteristic (ROC) curve was plotted for plasma galectin-3 in CHF. ResultsIn the present study, the mean age of CHF patients was 55.9±8.1 years and 54.1±9.4 years for controls. Males constituted 63.6% (n=35) and females were 36.4% (n=20) in the CHF group while 67.3% (n=37) were males and 32.7% (n=18) were females in the control group.The mean and SD for plasma galectin-3 was 9.95±2.8 ng/mL among CHF patients, while it was 4.08±1.3 ng/mL among controls (p<0.0001). As the age increased, levels of plasma galectin-3 increased in CHF patients and controls (p<0.00001). However, there was no statistical significance (p >0.05) for levels of galectin-3 among males and females in both groups. There was a highly significant difference in galectin-3 levels among cases and controls when classified into sub-groups based on their LVEF (p<0.0001). At the cut-off level of 8 ng/mL, plasma galectin-3 had a sensitivity of 92% and specificity of 71% in predicting CHF. ConclusionGalectin-3 helps in identifying CHF due to maladaptive remodeling of the heart. The present study concludes that estimating the plasma levels of galectin-3 is useful in diagnosing CHF.

show abstract

Section: Discussionsupporting

confidence: 92%

Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study

Bi¹,

Santhosh²,

Sigamani³

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Galectin-3, a soluble β-galactoside-binding lectin involved in cell proliferation, adhesion, migration and apoptosis, appears to promote inflammation or tissue fibrosis. Over the past decades, the prognostic role of serum galectin-3 as a biomarker linking oxidative stress, inflammation and fibrosis has been demonstrated in many pathological conditions such as HF, atherosclerosis, CKD and cancer 5 , 20 – 22 . Especially in patients with CKD, a recent large meta-analysis of 5226 patients showed that high galectin-3 levels were associated with an increased risk of all-cause mortality and CV events 10 .…”

Section: Discussionmentioning

confidence: 99%

Mediating effect of vascular calcification in galectin-3-related mortality in hemodialysis patients

Kim,

Noh,

Song

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Galectin-3 levels have been studied as a potential biomarker for predicting cardiovascular (CV) risk and mortality in hemodialysis (HD) patients. Recently, a close relationship between galectin-3 and vascular calcification (VC) has been reported. Here, we investigated the role of VC as a mediating factor in the association between galectin-3 and mortality. Serum galectin-3 and baseline aortic arch calcification (AoAC) score were measured in 477 incident HD patients. Mortality data were obtained at a median follow-up of 40 months. Causal mediation analysis was performed to examine the effect of vascular risk factors on galectin-3-related mortality. The prevalence of AoAC in HD patients was 57% (n = 272), and elevated galectin-3 levels were associated with a significantly increased risk of AoAC. When the galectin-3 level was divided by the median level of 37 ng/mL, a higher galectin group increased the risk of all-cause mortality by 1.71-fold (95% CI 1.02–2.92, p = 0.048), even after adjustment for multiple CV risk factors. Mediation analysis showed that both the direct effect of the galectin-3 on mortality (β = 0.0368, bootstrapped 95% CI [0.0113–0.0622]) and the indirect effects were significant. AoAC score and high-sensitivity CRP levels significantly mediated the association between galectin-3 and mortality (total indirect effects: β = 0.0188, bootstrapped 95% CI [0.0066–0.0352]). This study suggests that the association between high galectin-3 and mortality may be partially mediated by higher VC and inflammatory state in HD patients.

show abstract

“…However, other studies, such as the one conducted by de Boer et al, showed that the prognostic value of Gal-3 stands out only in those patients with HF and preserved left ventricular ejection fraction (LVEF) [ 44 ]. One meta-analysis claimed that Gal-3 can be used as a predictor for new-onset HF with preserved LVEF, which also correlates with left ventricular diastolic dysfunction [ 45 ]. A recent review article confirmed these findings and proposed Gal-3 as a marker that can guide the therapeutic approach in HF with preserved LVEF [ 46 ].…”

Section: Gal-3 and Cardiac Remodelingmentioning

confidence: 99%

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Făgărășan

Săsăran

Gozar

et al. 2023

IJMS

View full text Add to dashboard Cite

Galectin-3 (Gal-3) is a novel pro-fibrotic biomarker that can predict both right and left cardiac dysfunction caused by various cardiovascular conditions. Its expression seems to be progressively altered with evolving cardiac remodeling processes, even before the onset of heart failure. Hence, Gal-3 has been found to be an individual predictor of acute and chronic heart failure or to serve as part of an integrated biomarker panel that can foresee adverse cardiac outcomes. In congenital heart disease (CHD), Gal-3 correlates with cardiac mortality and complications in both children and adults and is proposed as a therapeutic target in order to reverse the activation of pro-fibrosis pathways that lead to heart failure. Positive associations between serum Gal-3 levels, post-operatory hospitalization rates, complications and ventricular dysfunction have also been reported within studies conducted on patients with CHD who underwent corrective surgery. Thus, this review tried to address the potential utility of Gal-3 in patients with CHD and particularly in those who undergo corrective surgery. The heterogeneity of the literature data and the lack of validation of the results obtained by the current studies on larger cohorts cannot be neglected, though. Further longitudinal research is required to establish how Gal-3 can relate to long-term outcomes in pediatric CHD.

show abstract

Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis

Cited by 15 publications

References 62 publications

Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study

Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study

Mediating effect of vascular calcification in galectin-3-related mortality in hemodialysis patients

The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature

Contact Info

Product

Resources

About